Tobacco use kills more than 7 million people worldwide each year, including 1.3 million who die from the effects of exposure to secondhand smoke.1 As a major contributor to cancer, cardiovascular ...

The planned implementation of Medicaid work requirements provides an opportunity to obtain longitudinal data to guide Medicaid policy, including data on health consequences for people who lose ...

Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome.

Syphilis is one of the oldest known diseases. Approximately 209,000 cases were reported in the United States in 2023 — the highest number of reported cases since 1950 — including nearly 4000 ...

Patients who have taken opioids for years for chronic pain must be treated differently from those who have not because such therapies cause profound physiological and neurologic changes. Reflexive ...

A 75-year-old man with chronic obstructive pulmonary disease underwent lung-volume–reduction surgery. Postoperatively, severe subcutaneous emphysema developed.

Network biologists, in focusing on interrelational structures emerging from complex interactions among genes, proteins, internal milieu, and external environment, echo the social science view that ...

The story of the patient-safety movement is one of slow progress punctuated by episodes of inspiring successes that are slow to be replicated. So it is not surprising that when promising innovations ...

Countries that rely more on price regulation and public financing might be expected to be less vulnerable to corporate influences in health care. But private equity firms are making inroads in vari ...

A tool used by the government for substance-use surveillance has consistently reported low rates of OUD. But the survey excluded a large group of Americans with OUD: people who take opioids as pres ...

A 68-year-old woman living in Japan presented with a 5-day history of rash and fevers. She had been bitten by a tick 1 week earlier. Examination revealed a petechial rash and eschar on the ankle.

In this registrational, phase 2 clinical study, we assigned patients with advanced NRG1 fusion–positive cancer involving any tumor type to receive zenocutuzumab at a dose of 750 mg intravenously every ...